¡¾¹Ø¼ü´Ê¡¿ ½áºË·ÖÖ§¸Ë¾ú£»rPOB»ùÒò£»KatG»ùÒò£»rpsL»ùÒò£»SSCP£»Ò©ÎïÄÍÊÜÐÔ
Studies of Mycobacterium tuberculosis multi-drug resistant gene
¡¾Abstract¡¿ Objective To evaluat the importance of rPOB¡¢KatG and rpsL gene mutation detection in multi-drug resistant clinical isolates of Mycobacterium tuberculosis. Methods rPOB¡¢KatG and rpsL gene mutation of 54multi-drug resistant clinical isolates£¬which is INH RFP and Sm resistance and 54 drug susceptible strains were analyzed using polymerase chain reaction-single strand conformation (PCR-SSCP).Results SSCP pattern of H37RV strain as control£¬SSCP pattern of rPOB£¬rpsL PCR amplification from drug susceptible strains were all the same as control. The specificity was 100%. However£¬the different SSCP pattern of KatG gene were found in 2 susceptible strains. The specificity was 96.3%. Gene deletion of rPOB¡¢KatG and rpsL were not found in all clinical isolates tested. SSCP patterns of rPOB gene were different from control in 49 drug resistant clinical isolates. SSCP patterns of KatG gene were different from control in 32drug resistant clinical isolates£¬SSCP pattern of rpsL gene were different from control in 40 drug resistant clinical isolates. The sensitivity were 90.1% (rPOB)£¬59.3% (KatG) and rpsl (74.1%)£¬respectively. Conclusion The major mechanism of RFP£¬INH£¬SM resistant drug was rPOB¡¢KatG and rpsL gene mutation£¬respectively PCR-SSCP may be one of the way which applied to drug resistant detection of Mycobacterium tuberculosis.
¡¾Key words¡¿ Mycobacterium tuberculosis£»rPOB gene£»KatG gene£»rpsL gene£»SSCP£»drug tolerance
ÎÒ¹úÊǽáºË²¡ÒßÇé×îÑÏÖØµÄ¹ú¼ÒÖ®Ò»£¬ÆäÖ÷ÒªÔÒòÊÇÄÍÒ©£¨DR-TB£©ºÍÄͶàÒ©£¨MDR-TB£©½áºË²¡µÄ¹ã·º·Ö²¼ºÍѸËÙ´«²¥¡£ÓÉÓÚµ¥Ò©»¯ÁƺͲ»¹æÔò»¯ÁÆ£¬ÆäÄÍÒ©Çé¿öÔ½À´Ô½ÑÏÖØ¡£½üÄêÀ´Ëæ×Å·Ö×ÓÉúÎïѧµÄÑо¿½øÕ¹ÈËÃǶԿ¹½áºË·ÖÖ¦¸Ë¾úµÄÒ©Àí×÷ÓÃλµãºÍ½áºË·ÖÖ¦¸Ë¾úÄÍÒ©»úÖÆ£¬ÓÈÆäÊÇÄÍÒìÑÌë¡¢Àû¸£Æ½ºÍÁ´Ã¹ËØ¡£Ä¿Ç°£¬½áºË·ÖÖ§¸Ë¾úÄÍÒ©ÐԲⶨÈÔ¶à²ÉÓþø¶ÔŨ¶È·¨¡¢±ÈÀý·¨µÈ¾µä·½·¨¡£µ«ÓÉÓÚ½áºË·ÖÖ§¸Ë¾úÉú³¤»ºÂý£¬¶øÄÍÒ©½áºË·ÖÖ§¸Ë¾úÉú³¤¸üΪ»ºÂý£¬ÆäÄÍÒ©ÐԲⶨÐè6¡«8ÖÜÉõÖÁ¸ü³¤£¬²»Äܼ°Ê±Ö¸µ¼ÁÙ´²ÓÃÒ©¡£Ð½ø¿ªÕ¹µÄBactec·¨Ò©Ãô¼ì²âÒòÆä¼Û¸ñ°º¹óµÈÖî¶à²»±ãÏÞÖÆÁËÆä¹ã·ºÊ¹Ó᣾ݱ¨µÀ£Û1£ÝINHÄÍÒ©Óë¹ýÑõ»¯Çâø-¹ýÑõ»¯ÎïøµÄ±àÂë»ùÒò£¨KatG£©Óйء¢¶øÄ³Ð©½áºË·ÖÖ§¸Ë¾úÄÍSMµÄ²úÉúÊÇÓÉÓÚÆäºËÌÇÌåµ°°×S12±àÂë»ùÒò£¨rpsL£©ºÍ16SrRNA±àÂë»ùÒò£¨rrs£©Í»±äËùÖ£Û2£Ý£¬Í¬Ê±Ò²Ö¤ÊµÁ˽áºË·ÖÖ§¸Ë¾úÄÍÀû¸£Æ½ÓëRNA¾ÛºÏøµÄ¦ÂÑÇ»ùµÄ±àÂë»ùÒòrPOBµÄÍ»±äÓйأÛ3£Ý¡£±ÊÕß²ÉPCR-SSCPÒøÈ¾·¨¶Ô54Àý£¨Í¬Ê±ÄÍINH¡¢RFP¡¢SM£©ºÍ45Àý£¨Ò©ÎïÃô¸Ð£©·Î½áºË²¡ÈË̵±ê±¾ÁÙ´²·ÖÀëÖêͬʱ½øÐÐKatG»ùÒò¡¢rPOB»ùÒòºÍrpsL»ùÒòÍ»±ä·ÖÎö¡£
1 ²ÄÁÏÓë·½·¨
1.1 ¾úÖêÀ´Ô´ H37RV±ê×¼ÖêÀ´Ô´ÓÚÖйúÒ©Æ·ÉúÎïÖÆÆ·¼ì¶¨Ëù£¬45ÀýÃô¸ÐÖêºÍ54ÀýͬʱÄÍINH¡¢RFP¡¢SMµÄÁÙ´²·ÖÀëÖêÀ´×ÔÖ麣ÊÐÈËÃñÒ½Ôº¡¢ÉòÑôÊÐÐØ¿ÆÒ½ÔºµÈ¡£°´½áºË²¡Õï¶Ïϸ¾úѧ¹æ³Ì½øÐоúÖÖ¼ø¶¨¼°Ò©ÃôÊÔÑé֤ʵΪ½áºË·ÖÖ§¸Ë¾ú£¬ÄÍÒ©ÖêÔòͬʱ¶ÔÒìÑÌë¡¢Àû¸£Æ½¡¢Á´Ã¹ËØÄÍÒ©¡£Ò©ÎïµÄ×î¸ßŨ¶ÈΪÒìÑÌëÂ10mg/L¡¢Àû¸£Æ½250mg/L¡¢Á´Ã¹ËØ100mg/L¡£
1.2 ·½·¨
1.2.1 ϸ¾úDNAÖÆ±¸ ÁÙ´²·ÖÀëÖêDNAÓ󣹿·Ó/ÂÈ·ÂÌáÈ¡£¬²¢½«´¿»¯ºóµÄÌáÈ¡ÎïÖÃÓÚ£20¡æ±£´æ±¸Óá£
1.2.2 PCRÀ©Ôö ²ÉÓÃ25¦Ìl·´Ó¦Ìåϵ£¬4xdNTPsÖÕŨ¶ÈΪ0.2mmol/L£¬ÒýÎïÖÕŨ¶ÈΪ0.2¦Ìmol/L£¬ÖÃDNAÀ©ÔöÒÇÀ©Ôö£¬À©Ôö²úÎï¾2%ÇíÖ¬ÌÇÄý½ºµçÓ¾¡£×ÏÍâ¼ì²ârPOB³öÏÖ258bpÌõ´ø¡¢KatG³öÏÖ282bpÌõ´ø¡¢rpsL³öÏÖ267bpÌõ´ø¼´ÎªÀ©ÔöÑôÐÔ¡£
1.2.3 SSCPÒøÈ¾ PCRÀ©ÔöÑôÐԵı걾½øÐÐSSCP¼ì²â£¬À©Ôö²úÎï¼ÓµÈÁ¿¼×õ£°·±äÐÔÒº95¡æ±äÐÔ10min£¬Á¢¼´±ùÔ¡5min£¬ÔÚ8%·Ç±äÐÔ¾Û±ûÏ©õ£°·Äý½ºÖеçÓ¾£¬Ìõ¼þΪ6¡æ¡¢100Vµçѹ£¬µçÓ¾Ô¼2¡«3h£¬µçÓ¾½áÊøºó£¬È¡Äý½º°åÐÐÏõËáÒøÈ¾É«£¬¹Û²ì½á¹û²¢ÕÕÏà¡£